Zika Virus Vaccine Development

Journal of Infectious Diseases

Volumn 216, Issue , 2017, Pages S957-S963

  Morabito, Kaitlyn M ^a   Graham, Barney S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

chimeric; DNA; live attenuated; mRNA; vaccine development; whole inactivated; Zika virus

Indexed keywords

ANTIGEN; CHIMERIC PROTEIN; DNA VACCINE; GLS 5700; INACTIVATED VACCINE; LIVE VACCINE; MICRORNA 1325; NUCLEIC ACID VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; VRC 5283; VRC 5288; WEST NILE VACCINE; ZIKA VIRUS PURIFIED INACTIVATED VIRUS VACCINE; ZIKA VIRUS VACCINE; ZIKA VIRUS VACCINE 17F YF;

AEDES AEGYPTI; ANTIGEN STRUCTURE; ARTICLE; DRUG DESIGN; FLAVIVIRUS INFECTION; GENE VECTOR; GOVERNMENT; HISTORY; HUMAN; IMMUNE RESPONSE; KNOWLEDGE; MEDICAL SOCIETY; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; VACCINE PRODUCTION; ZIKA FEVER; ZIKA VIRUS; GENETICS; IMMUNOLOGY; PUBLIC HEALTH; VIROLOGY;

HUMANS; PUBLIC HEALTH; VIRAL VACCINES; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85040245665     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix464     Document Type: Article

References (55)

1. Dick GW, Haddow AJ. Uganda S virus; a hitherto unrecorded virus isolated from mosquitoes in Uganda. I. Isolation and pathogenicity. Trans R Soc Trop Med Hyg 1952; 46:600-18.
2. Cauchemez S, Besnard M, Bompard P, et al. Association between Zika virus and microcephaly in French Polynesia, 2013-15: a retrospective study. Lancet 2016; 387:2125-32.
3. Brasil P, Pereira JP Jr, Moreira ME, et al. Zika virus infection in pregnant women in Rio de Janeiro. N Engl J Med 2016; 375:2321-34.
4. Duffy MR, Chen TH, Hancock WT, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med 2009; 360:2536-43.
5. Brasil P, Sequeira PC, Freitas AD, et al. Guillain-Barre syndrome associated with Zika virus infection. Lancet 2016; 387:1482.
6. Marano G, Pupella S, Vaglio S, Liumbruno GM, Grazzini G. Zika virus and the never-ending story of emerging pathogens and transfusion medicine. Blood Transfus 2016; 14:95-100.
7. Moore CA, Staples JE, Dobyns WB, et al. Characterizing the pattern of anomalies in congenital Zika syndrome for pediatric clinicians. JAMA Pediatr 2017; 171:288-95.
8. Honein MA, Dawson AL, Petersen EE, et al.; US Zika Pregnancy Registry Collaboration. Birth defects among fetuses and infants of us women with evidence of possible Zika virus infection during pregnancy. JAMA 2017; 317:59-68.
9. Johansson MA, Mier-y-Teran-Romero L, Reefhuis J, Gilboa SM, Hills SL. Zika and the risk of microcephaly. N Engl J Med 2016; 375:1-4.
10. Melo AS, Aguiar RS, Amorim MM, et al. Congenital Zika virus infection: beyond neonatal microcephaly. JAMA Neurol 2016; 73:1407-16.
11. Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 2016; 387:1531-9.
12. Oehler E, Watrin L, Larre P, et al. Zika virus infection complicated by Guillain-Barre syndrome-case report, French Polynesia, December 2013. Euro Surveill 2014; 19:pii: 20720.
13. Papania MJ, Wallace GS, Rota PA, et al. Elimination of endemic measles, rubella, and congenital rubella syndrome from the Western hemisphere: the US experience. JAMA Pediatr 2014; 168:148-55.
14. Smit R, Postma MJ. Review of tick-borne encephalitis and vaccines: clinical and economical aspects. Expert Rev Vaccines 2015; 14:737-47.
15. Halstead SB, Thomas SJ. New Japanese encephalitis vaccines: alternatives to production in mouse brain. Expert Rev Vaccines 2011; 10:355-64.
16. Staples JE, Monath TP. Yellow fever: 100 years of discovery. JAMA 2008; 300:960-2.
17. Flipse J, Smit JM. The complexity of a dengue vaccine: a review of the human antibody response. PLoS Negl Trop Dis 2015; 9:e0003749.
18. Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011; 29:7229-41.
19. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, et al.; CYD-TDV Dengue Vaccine Working Group. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 2015; 373:1195-206.
20. Durbin AP, Kirkpatrick BD, Pierce KK, Schmidt AC, Whitehead SS. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 2011; 29:7242-50.
21. Whitehead SS, Durbin AP, Pierce KK, et al. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. PLoS Negl Trop Dis 2017; 11:e0005584.
22. Osorio JE, Velez ID, Thomson C, et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect Dis 2014; 14:830-8.
23. Osorio JE, Wallace D, Stinchcomb DT. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone. Expert Rev Vaccines 2016; 15:497-508.
24. Netland J, Bevan MJ. CD8 and CD4 T cells in West Nile virus immunity and pathogenesis. Viruses 2013; 5:2573-84.
25. Rivino L, Lim MQ. CD4+ and CD8+ T-cell immunity to dengue-lessons for the study of Zika virus. Immunology 2017; 150:146-54.
26. Winkler CW, Myers LM, Woods TA, et al. Adaptive immune responses to Zika virus are important for controlling virus infection and preventing infection in brain and testes. J Immunol 2017; 198:3526-35.
27. Elong Ngono A, Vizcarra EA, Tang WW, et al. Mapping and role of the CD8+ T cell response during primary Zika virus infection in mice. Cell Host Microbe 2017; 21:35-46.
28. Wen J, Tang WW, Sheets N, et al. Identification of Zika virus epitopes reveals immunodominant and protective roles for dengue virus cross-reactive CD8+ T cells. Nat Microbiol 2017; 2:17036.
29. Van Gessel Y, Klade CS, Putnak R, et al. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO®) induced neutralizing antibody titers. Vaccine 2011; 29:5925-31.
30. Julander JG, Trent DW, Monath TP. Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine 2011; 29:6008-16.
31. Kreil TR, Burger I, Bachmann M, Fraiss S, Eibl MM. Antibodies protect mice against challenge with tick-borne encephalitis virus (TBEV)-infected macrophages. Clin Exp Immunol 1997; 110:358-61.
32. Richner JM, Himansu S, Dowd KA, et al. Modified mRNA vaccines protect against Zika virus infection. Cell 2017; 168:1114-25.e10.
33. Dowd KA, Ko SY, Morabito KM, et al. Rapid development of a DNA vaccine for Zika virus. Science 2016; 354:237-40.
34. Muthumani K, Griffin BD, Agarwal S, et al. In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine. NPJ Vaccines 2016; 1:16021.
35. Larocca RA, Abbink P, Peron JP, et al. Vaccine protection against Zika virus from Brazil. Nature 2016; 536:474-8.
36. Abbink P, Larocca RA, De La Barrera RA, et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 2016; 353:1129-32.
37. Dowd KA, DeMaso CR, Pelc RS, et al. Broadly neutralizing activity of Zika virus-immune sera identifies a single viral serotype. Cell Rep 2016; 16:1485-91.
38. Zhao H, Fernandez E, Dowd KA, et al. Structural basis of Zika virus-specific antibody protection. Cell 2016; 166:1016-27.
39. Rouvinski A, Guardado-Calvo P, Barba-Spaeth G, et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 2015; 520:109-13.
40. Kaufmann B, Vogt MR, Goudsmit J, et al. Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc Natl Acad Sci U S A 2010; 107:18950-5.
41. de Alwis R, Smith SA, Olivarez NP, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A 2012; 109:7439-44.
42. Vogt MR, Dowd KA, Engle M, et al. Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcγ receptor and complement-dependent effector mechanisms. J Virol 2011; 85:11567-80.
43. Dai L, Song J, Lu X, et al. Structures of the Zika virus envelope protein and its complex with a flavivirus broadly protective antibody. Cell Host Microbe 2016; 19:696-704.
44. Cherrier MV, Kaufmann B, Nybakken GE, et al. Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J 2009; 28:3269-76.
45. Ferlenghi I, Clarke M, Ruttan T, et al. Molecular organization of a recombinant subviral particle from tick-borne encephalitis virus. Mol Cell 2001; 7:593-602.
46. Weissman D. mRNA transcript therapy. Expert Rev Vaccines 2015; 14:265-81.
47. Sahin U, Kariko K, Tureci O. mRNA-based therapeutics-developing a new class of drugs. Nat Rev Drug Discov 2014; 13:759-80.
48. Deering RP, Kommareddy S, Ulmer JB, Brito LA, Geall AJ. Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines. Expert Opin Drug Deliv 2014; 11:885-99.
49. Pardi N, Hogan MJ, Pelc RS, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 2017; 543:248-51.
50. Richner JM, Himansu S, Dowd KA, et al. Modified mRNA vaccines protect against Zika virus infection. Cell 2017; 169:176.
51. Heinz FX, Stiasny K. Flaviviruses and flavivirus vaccines. Vaccine 2012; 30:4301-6.
52. Sumathy K, Kulkarni B, Gondu RK, et al. Protective efficacy of Zika vaccine in AG129 mouse model. Sci Rep 2017; 7:46375.
53. Tauber E, Kollaritsch H, Korinek M, et al. Safety and immunogenicity of a Verocell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 2007; 370:1847-53.
54. Shan C, Muruato AE, Jagger BW, et al. A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and tetis damage. Nat Commun 2017; 8:676.
55. Shan C, Muruato AE, Nunes BTD, et al. A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models. Nat Med 2017; 23:763-7.